Foreign capital isn't just coming back to China — it's coming back through a different door. Less greenfield, more dealmaking. If your China strategy memo still assumes "entry = set up a WFOE," the buy-side playbook may already be a step ahead of it.
The shift is visible in the deal data: a growing share of China's largest M&A transactions now involve a foreign buyer, and technology and biotech account for a large slice of this year's deal value. Where the licence, the team and the pipeline already exist, acquiring or partnering beats a three-year build. Three forces are driving it.
1. Policy is actively courting it
Recent action plans on foreign investment specifically flag smoother cross-border M&A procedures, and the M&A rules under the Foreign Investment Law framework are being amended — including simpler cross-border share swaps. The direction of travel is toward making deals easier, not harder.
2. The targets have changed
Biotech and technology now account for a large share of deal value, and the marquee transactions increasingly take the shape of licensing partnerships and stakes rather than sprawling, capital-heavy greenfield projects. Capital isn't leaving China — it's changing shape, toward focused bets on technology, R&D and services.
3. Buying is faster than building
In sectors where the licence, team and pipeline already exist, acquiring or partnering gets you to market in a fraction of the time a greenfield entry would take. For many boards weighing a China move, "buy" has quietly become the faster route than "build."
The caveat: the doorway is still narrow
An acquisition runs through gates a greenfield entry never meets — merger control, national-security review, and foreign-exchange approvals. Deals have been unwound after completion when those gates weren't cleared. The door is more open than it was; the doorway is still narrow, and it's the approvals that decide whether a deal holds.
For foreign companies re-examining China in 2026, the practical takeaway is to run build-vs-buy as a real comparison — and, on the buy-side, to map merger control, security review and FX at the top of the process, not the end of it.
Frequently asked questions
Often, yes — where the licence, team and pipeline already exist, buying can beat a multi-year greenfield build. But an acquisition adds regulatory gates (merger control, security review, FX) that a fresh setup doesn't, so the timing advantage depends on clearing those cleanly.
Typically merger control, national-security review, foreign-investment filings and foreign-exchange registration — mapped and sequenced early, because deals can be unwound if those gates aren't cleared.
This article is general information for foreign companies, not legal advice on any specific matter. Rules and practice change; please take advice on your facts.